Placeholder Banner

BIO Submits Comments to FDA's Draft EA and Preliminary FONSI Regarding the Proposed Field Trial of the OX513A Strain of Aedes aegypti (Ae. aegypti)

May 18, 2016
Ae. aegypti, a non-native mosquito species that survives exceptionally well in urban environments, is the primary vector for yellow fever, a disease that is experiencing a resurgence in some tropical countries2. Ae. aegypti mosquitoes also carry and transmit other viruses – Zika, dengue, and chikungunya – that can lead to a number of devastating diseases, such as hemorrhagic fever, microcephaly in infants, Guillain-Barré syndrome, and other neurological disorders. Five field tests in three other countries have proven the release of OX513A mosquitoes is an effective method for decreasing the size of Ae. aegypti populations. These results are consistent with FDA’s preliminary FONSI. The FONSI is well-reasoned and fully supported by the analysis in the draft EA. BIO urges FDA to move forward expeditiously, given the global threat to public health3 posed by Ae. aegypti.
Download Full Comments Below
BIO Comments FDA CVM Oxitec Field Trials
Read BIO's Comments Here in their Entirety
Discover More
We write as a coalition of advocates for the startup ecosystem to voice our strong support for the IGNITE American Innovation Act, legislation to support startups through the economic crisis by allowing companies to monetize tax assets generated…
The Biotechnology Innovation Organization (BIO) is pleased to respond to the U.S. Department of Agriculture’s (USDA) Solicitation of Input from Stakeholders on Agricultural Innovations. BIO applauds USDA for taking a proactive approach and seeking…
July 31, 2020 Re: Docket No. FDA–2020-N-0837: Raare Disease Clinical Trial Network; Request for Information. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the…